44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617 ; volume:7 ; number:1 ; day:19 ; month:1 ; year:2017 ; pages:1-10 ; date:12.2017
EJNMMI Research ; 7, Heft 1 (19.1.2017), 1-10, 12.2017
- Classification
-
Biowissenschaften, Biologie
- Keyword
-
Arzneimittelentwicklung
Arzneimitteldesign
- Creator
-
Umbricht, Christoph A.
- Contributor
-
Benešová, Martina
Schmid, Raffaella M.
Türler, Andreas
Schibli, Roger
Van der Meulen, Nicholas P.
Müller, Cristina
SpringerLink (Online service)
- DOI
-
10.1186/s13550-017-0257-4
- URN
-
urn:nbn:de:1111-2017021511276
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Umbricht, Christoph A.
- Benešová, Martina
- Schmid, Raffaella M.
- Türler, Andreas
- Schibli, Roger
- Van der Meulen, Nicholas P.
- Müller, Cristina
- SpringerLink (Online service)
Other Objects (12)
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment
Nebenwirkungen und Ansprechen nach einer Radioligandentherapie mit 177Lu-DKFZ-PSMA-617
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Wirksamkeit und Sicherheit der Radioligandentherapie mit 177Lu-PSMA-617 bei Patienten mit mCRPC und niedriger PSMA-Expression
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment
Nebenwirkungen und Ansprechen nach einer Radioligandentherapie mit 177Lu-DKFZ-PSMA-617
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Wirksamkeit und Sicherheit der Radioligandentherapie mit 177Lu-PSMA-617 bei Patienten mit mCRPC und niedriger PSMA-Expression
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
PET-bildgebendes Ansprechen einer Tandem 225Ac-PSMA-617/177Lu-PSMA-617- Radioligandentherapie bei Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom
A pilot study of 68 Ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma
[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment
Nebenwirkungen und Ansprechen nach einer Radioligandentherapie mit 177Lu-DKFZ-PSMA-617
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Wirksamkeit und Sicherheit der Radioligandentherapie mit 177Lu-PSMA-617 bei Patienten mit mCRPC und niedriger PSMA-Expression
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007